Welcome to our dedicated page for Argan SEC filings (Ticker: AGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Argan, Inc. (NYSE: AGX) is a Delaware corporation whose common stock is listed on the New York Stock Exchange, and it files periodic and current reports with the U.S. Securities and Exchange Commission. This SEC filings page brings together Argan’s Forms 10-K and 10-Q, as well as its frequent Form 8-K current reports, which disclose material events such as financial results, major project contracts and dividend declarations.
In its Form 8-K filings, Argan reports items like quarterly earnings releases under results of operations and financial condition, regular quarterly cash dividend announcements, and significant EPC contract awards received by subsidiaries such as Gemma Power Systems and Atlantic Projects Company. These filings also confirm key corporate details, including Argan’s state of incorporation, the AGX trading symbol and its New York Stock Exchange listing.
For investors and analysts, Argan’s annual reports on Form 10-K and quarterly reports on Form 10-Q provide more comprehensive information on segment performance, project backlog, risk factors and accounting policies, while current reports on Form 8-K highlight specific developments between reporting periods. Filings may also describe how new EPC contracts, full notices to proceed and backlog additions affect the company’s future activity.
On this page, AI-powered tools summarize lengthy SEC documents, highlight the main points from Argan’s 10-K and 10-Q filings, and explain the significance of individual 8-K items, such as dividend changes or large contract awards. Users can also review insider and executive-related filings like Form 4, along with proxy materials, to gain additional insight into Argan’s governance and equity activity.
ARGAN INC executive Charles Edwin Collins IV, CEO of Gemma, reported option exercises and share sales in April 2026. He exercised stock options to acquire a total of 13,568 shares of common stock at exercise prices ranging from $33.81 to $148.72 per share.
On April 20, 2026, he exercised an option for 2,500 shares at $39.47 per share and sold 2,500 shares at $610 per share. On April 21, 2026, he exercised additional options totaling 11,068 shares and sold 11,068 shares at an average price of $621.61 per share. Following these transactions, he directly holds 30,320 shares of ARGAN common stock.
ARGAN INC director Jeffrey John Ronald Jr. reported an option exercise and share sale. On April 21, 2026, he exercised a stock option for 5,000 shares of common stock at $37.13 per share using a net settle method, receiving 4,698 shares of common stock.
That same day, he sold 3,636 shares of common stock in open-market transactions at an average price of $615.40 per share. After these transactions, he held 4,698 shares directly and 8,000 shares indirectly through a John R. Jeffrey IRA.
Argan, Inc. is asking stockholders to elect nine directors, approve an advisory say‑on‑pay vote, and ratify Grant Thornton LLP as auditor at its June 10, 2026 annual meeting in Arlington, Virginia. Only holders of record on April 16, 2026 may vote.
The proxy highlights strong recent performance: Fiscal 2026 revenues were $945 million, net income was $138 million, diluted EPS was $9.74, and EBITDA was $163 million. Cash, cash equivalents and short‑term investments totaled $895 million with net liquidity of $421 million and no debt, while project backlog reached $2.93 billion.
Over five years, Argan’s cumulative total stockholder return rose to $886.07 on a $100 base, outpacing the S&P 500 and a heavy construction index. The company raised its quarterly dividend by 33% to an annual rate of $2.00 per share and expanded its share repurchase authorization to $200 million through January 31, 2030. The proxy also details an independent, committee‑driven board structure, tighter stock ownership guidelines for directors and executives, expanded performance‑based equity, and a clawback, anti‑hedging, and no‑pledging framework.
Argan, Inc. submitted a Form 144 notice related to proposed sales of Common Stock by an insider. The filing lists an option exercise/equity grant for 3,636 shares on 01/16/2026 and shows prior sales of 5,000 shares on 01/27/2026 and 4,556 shares on 03/31/2026 (proceeds $2,459,556.60 for the 03/31/2026 sale). The notice names John R. Jeffrey, Jr. as the selling person and lists broker information for Charles Schwab & Co.
ARGAN INC executive Charles Edwin Collins IV, CEO of Gemma, reported multiple equity award vestings and option exercises that increased his direct holdings. On April 16–17, 2026, he exercised derivative awards to acquire a total of 13,166 shares of common stock, all coded as option or unit exercises rather than open-market purchases or sales.
Following these transactions, he directly owned 30,320 shares of common stock. Footnotes explain that the vested awards include Renewable Performance-Based Restricted Stock Units, Time-Based Restricted Stock Units, Earnings Per Share Performance-Based Restricted Stock Units, and other performance-based units granted in prior years, which became issuable in 2026 under their one- and three-year vesting schedules.
ARGAN INC President and CEO David Hibbert Watson reported multiple equity award vestings and one stock sale. On April 17, 2026, he sold 19,310 shares of common stock in the open market at an average price of $602.11 per share, and held 49,998 shares directly afterward. Around the same time, several restricted stock unit awards vested, including time-based RSUs and performance-based RSUs. Footnotes state that 20,000 shares became issuable from earnings-per-share performance-based RSUs versus a 10,000-share target, and 10,000 shares became issuable from performance-based RSUs versus a 5,000-share target, indicating awards paid out above target levels.
ARGAN INC Chief Financial Officer Joshua Scott Baugher reported a mix of equity exercises and sales. On April 16 and 17, 2026, several tranches of Time-Based Restricted Stock Units vested under three-year schedules, resulting in exercises covering a total of 2,251 shares of common stock.
On April 16, 2026, he sold 600 shares of common stock in an open-market transaction at an average price of $605.60 per share, while retaining the remainder. Following these transactions, he directly holds 1,784 shares of common stock and 2,459 Time-Based Restricted Stock Units.
ARGAN INC director Lisa Larroque Alexander reported routine equity compensation activity. On April 16, 2026, 695 Time-Based Restricted Stock Units vested and were converted into 695 shares of common stock, consistent with a one-year vesting schedule for TRSUs granted on April 16, 2025.
Following these transactions, she directly holds 700 shares of common stock and 530 Time-Based Restricted Stock Units. These entries reflect compensation-related derivative exercises rather than open-market buying or selling.